Jeffrey L. Lennox
Emory University(US)
Publications by Year
Research Areas
HIV Research and Treatment, HIV/AIDS drug development and treatment, HIV/AIDS Research and Interventions, HIV-related health complications and treatments, Pneumocystis jirovecii pneumonia detection and treatment
Most-Cited Works
- → Raltegravir with Optimized Background Therapy for Resistant HIV-1 Infection(2008)683 cited
- → Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial(2009)619 cited
- → Guidelines for the Management of Chronic Kidney Disease in HIV-Infected Patients: Recommendations of the HIV Medicine Association of the Infectious Diseases Society of America(2005)584 cited
- → Subgroup and Resistance Analyses of Raltegravir for Resistant HIV-1 Infection(2008)505 cited
- → Clinical Practice Guideline for the Management of Chronic Kidney Disease in Patients Infected With HIV: 2014 Update by the HIV Medicine Association of the Infectious Diseases Society of America(2014)305 cited
- → Efficacy and Tolerability of 3 Nonnucleoside Reverse Transcriptase Inhibitor–Sparing Antiretroviral Regimens for Treatment-Naive Volunteers Infected With HIV-1(2014)258 cited
- → A dangerous dilemma: management of infectious intracranial aneurysms complicating endocarditis(2006)240 cited
- → Raltegravir Versus Efavirenz Regimens in Treatment-Naive HIV-1–Infected Patients: 96-Week Efficacy, Durability, Subgroup, Safety, and Metabolic Analyses(2010)228 cited
- → Durable Efficacy and Safety of Raltegravir Versus Efavirenz When Combined With Tenofovir/Emtricitabine in Treatment-Naive HIV-1–Infected Patients(2013)211 cited
- → Long‐Term Efficacy and Safety of Raltegravir Combined with Optimized Background Therapy in Treatment‐Experienced Patients with Drug‐Resistant HIV Infection: Week 96 Results of the BENCHMRK 1 and 2 Phase III Trials(2010)204 cited